Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Daily Archives: December 17, 2020

You are here:
  1. Home
  2. 2020
  3. December
  4. 17

Masitinib in Alzheimer’s Disease Webcast Presentation

2020By Alexis BERNARDDecember 17, 2020

17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease

Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020

2020By Alexis BERNARDDecember 17, 2020

17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020

Corrective press release regarding adverse events information from study AB09004

2020By Alexis BERNARDDecember 17, 2020

17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020

AB Science
© AB Science – All right reserved
Go to Top